CClinicalTrials.gg
RecruitingNCT06173232Updated Dec 15, 2023

Assessment of Retinal Fundus Imaging Camera

An observational study in Diabetic Retinopathy and Diabetic Macular Edema, sponsored by Digital Diagnostics, Inc.. Recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by Digital Diagnostics, Inc. · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
22 Years and older
Sex
All
01

Study summary

The goal of this prospective study is to evaluate device performance when using fundus images taken from retinal fundus cameras in subjects with and without diabetic retinopathy per ETDRS level 35 and higher with or without macular edema.

Read the detailed description

The goal of this prospective study is to evaluate device performance when using fundus images taken from retinal fundus cameras in subjects with and without diabetic retinopathy (ETDRS level 35 and higher) with or without macular edema. Study subjects will sign the informed consent form, and data collection will involve being imaged by cameras.

02

Conditions studied

  • Diabetic Retinopathy
  • Diabetic Macular Edema
03

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A minimum of 80 eligible subjects, these subjects will be categorized as ETDRS ≥ 35 with or without DME and subjects with ETDRS 20 or less and no DME

Inclusion criteria

  • 22 years of age or older.
  • Documented diagnosis of diabetes mellitus, as per any of the following: Having met the criteria established by the World Health Organization (WHO) and/or the American Diabetes Association (ADA), Hemoglobin A1c (HbA1c) ≥ 6.5%, Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L), Oral Glucose Tolerance Test (OGTT) with two-hour plasma glucose (2-hr PG) ≥ 200 mg/dL (11.1 mmol/L), using the equivalent of an oral 75g anhydrous glucose dose dissolved in water, Symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose (RPG) ≥ 200 mg/dL (11.1 mmol/L)
  • Ability to understand and the willingness to sign a written informed consent document.
  • Diagnosis from a retinal specialist of ETDRS level of 35 or higher with or without DME or diagnosis from a retinal specialist of ETDRS level 20 or lower and no DME.
  • Standard Corrected Visual Acuity of at least 20/40 or better in both eyes.

Exclusion criteria

Exclusion Criteria:

  • Currently participating in an interventional eye study (e.g., actively receiving the investigational product for Diabetic Retinopathy (DR) and/or Diabetic Macular Edema (DME)).
  • Has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure or glycemic control, microphthalmia, or previous enucleation).
  • Pregnancy
  • Has a known allergy to or contraindication for the use of Tropicamide 1% or other mydriatic eye drops.
  • Any condition that is contraindicated for the use of study devices in the opinion of the investigator.
  • Contraindication for imaging by devices used in the study due to any of the following:
  • Subject is hypersensitive to light
  • Subject recently underwent photodynamic therapy (PDT)
  • Subject is taking medication that causes photosensitivity
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1

    Subjects with ETDRS ≥ 35 with or without DME

    Device: Camera Imaging

  • Group 2

    Subjects with ETDRS 20 or less and no DME

    Device: Camera Imaging

Interventions

  • DeviceCamera Imaging

    Camera Imaging

05

What researchers measure

Primary outcomes

  1. Primary Objective

    Agreement of AI device results (mtmDR(+), mtmDR(-)) obtained from fundus cameras

    Time frame: 1 Day

Other outcomes

  1. Exploratory Objective

    Agreement of AI device probability scores obtained from fundus cameras

    Time frame: 1 Day

  2. Exploratory Endpoint

    Agreement of AI device results (mtmDR(+), mtmDR(-), "Exam Quality Insufficient" obtained from fundus cameras

    Time frame: 1 Day

06

Study locations

1 of 1 sites recruiting
  • Midwest Eye Center
    Cincinnati, Ohio 45202, United States
    • Savannah Hollingsworth · Contact
    • Christopher Devine, MD · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06173232
Lead sponsor
Digital Diagnostics, Inc.
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Nov 20, 2023
Primary completion
Mar 2024 (estimated)
Completion
May 2024 (estimated)
Last update
Dec 15, 2023

Study contacts

Breanne MacMillan, MS
Contact
macmillan@digitaldiagnostics.com
815-931-1354
Audrey Singh, BS
study director · Digital Diagnostics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion